TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07093476: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Trial and Open-Label Extension Study to Evaluate the Efficacy and Safety of Add-On Therapy With Empagliflozin for Patients With Inadequately C

Sponsor: Celltrion · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 171 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07093476 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07093476 Rescue Dossier →